Copenhagen-based research center is awarded up to DKK 1 billion (€134.2 million) from the Novo Nordisk Foundation to support research toward innovative approaches to the diagnosis, prevention, and treatment of cardiometabolic diseases. COPENHAGEN, Denmark , April 25, 2023 /PRNewswire/ — The prevalence of cardiometabolic diseases such as diabetes, obesity and cardiovascular disease continues to increase […]
Author: Ken Dropiewski
ARCA biopharma Announces First Quarter 2023 Financial Results
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first […]
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
LONDON, April 24, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq […]
Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment System
The FreeClimb 70 Reperfusion System, powered by the Tenzing 7 delivery catheter, enables neurointerventionalists to address critical unmet needs in ischemic stroke treatment SAN MATEO, Calif., April 24, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular […]
Zylox-Tonbridge enters into strategic cooperation with Hicicare for innovative Chinese vascular guidewires solutions
HANGZHOU, China, April 23, 2023 /PRNewswire/ — Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, the “Company”) announced the signing of a strategic agreement with Guangdong Hicicare Science Co., Ltd. (“Hicicare”). With the collaboration, Zylox-Tonbridge and Hicicare plan to introduce and help accelerate the commercialization of co-branded vascular guidewire products in the neuro- […]
Capital Health Performs First Watchman Implant
Minimally invasive procedure dramatically reduces stroke risk for certain atrial fibrillation patients HOPEWELL, N.J., April 21, 2023 /PRNewswire/ — Physicians and staff from Capital Health’s Heart and Vascular Institute recently performed their first Watchman implant procedure at Capital Health Regional Medical Center in Trenton, New Jersey. Left atrial appendage closure, which includes the […]
Philips delivers solid operational performance as supply chain improves and actions to enhance execution start to take effect
First-quarter highlights Group sales increased to EUR 4.2 billion, with 6% comparable sales growth Comparable order intake growth was flat, with double-digit growth in the Diagnosis & Treatment businesses, offset by a decline in the Connected Care businesses Income from operations amounted to a loss of EUR 583 million, mainly […]
Picard Medical and its Subsidiary, SynCardia Systems, a Pioneer in Total Artificial Heart Technology, to Become a Publicly Traded Company via Merger with Altitude Acquisition Corp.
SynCardia Manufactures and Distributes the First-and-Only Commercially Available and FDA Approved Total Artificial Heart SynCardia is Entering a Rapid Growth Phase Supported by New Product Development, Label Expansion, and International Growth Transaction Estimates a Pre-Money Enterprise Value of $480 Million for Picard Medical Picard Medical Stockholders Will Roll 100% of Their Existing […]
ISHLT and ISHLT Foundation Fund Research and Career Development with Grants
Five grant recipients announced at Annual Meeting Chicago, IL, April 22, 2023 (GLOBE NEWSWIRE) — The International Society for Heart and Lung Transplantation (ISHLT) announced more than $400,000 USD in funding for research designed to improve care for patients with advanced heart and lung disease. The grants were funded by […]
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
NEW YORK & VERO BEACH, Fla.–(BUSINESS WIRE)–NASDAQ IVCP Swiftmerge Acquisition Corp (“Swiftmerge”), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, announced today the signing of a non-binding letter of intent (“LOI”) for a business combination with HDL Therapeutics Inc. (“HDL Therapeutics”), a privately held commercial […]



